Icosavax Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Icosavax wird ein Gewinn- und Umsatzwachstum von 20.9% bzw. 64.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 27.1% pro Jahr wachsen soll.

Wichtige Informationen

20.9%

Wachstumsrate der Gewinne

27.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	64.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	11 Jan 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Jul 28

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Mar 24

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Oct 29

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ICVX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	49	-123	-112	13	4
12/31/2025	1	-144	-126	-130	5
12/31/2024	N/A	-115	-112	-115	5
12/31/2023	N/A	-102	-87	-90	5
9/30/2023	N/A	-97	-76	-71	N/A
6/30/2023	N/A	-97	-79	-70	N/A
3/31/2023	N/A	-93	-77	-66	N/A
12/31/2022	1	-92	-73	-62	N/A
9/30/2022	3	-86	-72	-63	N/A
6/30/2022	4	-99	-60	-55	N/A
3/31/2022	6	-85	-54	-52	N/A
12/31/2021	8	-67	-40	-39	N/A
9/30/2021	7	-53	-30	-29	N/A
6/30/2021	6	-25	-23	-22	N/A
3/31/2021	4	-21	-15	-15	N/A
12/31/2020	2	-19	-14	-14	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ICVX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ICVX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ICVX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ICVX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ICVX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ICVX in 3 Jahren voraussichtlich hoch sein wird

Icosavax Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 12% to US$21.35

Price target increased by 14% to US$23.51

Price target decreased by 14% to US$20.69

Consensus forecasts updated

Consensus revenue estimates increase by 36%

Recent updates

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Chief Medical Officer notifies of intention to sell stock

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target decreased by 12% to US$21.35

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

President notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target increased by 14% to US$23.51

Icosavax, Inc. Announces Positive Topline Interim Results from Its Phase 1 Clinical Trial of Ivx-A12 Against Respiratory Syncytial Virus (Rsv) and Human Metapneumovirus (hMPV) in Older Adults

Chief Scientific Officer notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 14% to US$20.69

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

President notifies of intention to sell stock

Icosavax, Inc. Appoints Jennifer Raymond as Senior Vice President, Technical Operations

President notifies of intention to sell stock

Chief Scientific Officer recently sold US$219k worth of stock

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.30 loss in 3Q 2021)

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Icosavax, Inc. Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Icosavax GAAP EPS of -$0.57

Chief Scientific Officer notifies of intention to sell stock

Icosavax Announces Results from Ivx-411 Drug Product Investigation and Outlines Additional Corporate Milestones

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Icosavax, Inc. Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

Icosavax, Inc.(NasdaqGS:ICVX) dropped from Russell 2000 Growth Index

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

High number of new directors

Icosavax, Inc., Annual General Meeting, Jun 10, 2022

Independent Chair recently bought US$300k worth of stock

Consensus revenue estimates increase by 36%

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Treasurer & Chief Business Officer notifies of intention to sell stock

Insider exercised options to buy US$1.2m worth of stock.

Chief Medical Officer exercised options to buy US$897k worth of stock.

President exercised options and sold US$91k worth of stock

High number of new and inexperienced directors

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Icosavax, Inc. Announces the Initiation of A Phase 1/1B Clinical Trial of IVX-121

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken